Nature Reviews Neurology

Article	Citations
Lymphatic propagation of α-synuclein	456
Microglia, spreaders of Aβ seeds	403
Transmembrane protein interacts with α-synuclein to confer risk of PD	342
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	271
Ventricular enlargement caused by aducanumab	270
Getting specific: targeting Fc receptors in myasthenia gravis	244
Brain stimulation aids walking after spinal injury	241
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	226
Neural cell state shifts and fate loss in ageing and age-related diseases	223
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	208
Diagnosis and management of migraine in ten steps	192
Global synergistic actions to improve brain health for human development	186
Refining oxytocin therapy for autism: context is key	186
NODDI reveals brain microstructural changes in multiple sclerosis	185
Disease-specific modifications of tau protein	179
Continuous levodopa production by an artificial enzyme	174
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	173
The impact of rare genetic variants on Alzheimer disease	172
Spinal muscular atrophy treatment in utero	159
Nir Giladi (1955–2024)	157
Mitochondrial DNA instability in Huntington disease	155
Study reveals new ALS risk genes	134
Microglia subset associated with high-grade glioma	131
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	129
Is post-stroke cognitive impairment all about real estate?	128

TREM2 mediates phagocytosis in glioblastoma	126
Imperatives and co-benefits of research into climate change and neurological disease	119
SEQUINS — a new initiative to address disparities in neurology	118
The Digitized Memory Clinic	114
Amyloid-β: a potential link between epilepsy and cognitive decline	113
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	110
The role of the gut microbiota in multiple sclerosis	108
Ultrasound lets gene therapy into the brain	102
Brain volume is associated with cognition in MS	101
Role for endogenous retrovirus in FTD	99
Menopause influences tau pathology	98
Amyloid plaques: hotspots for microglial turnover	97
Neurological care for LGBT+ people	96
Psychosis-causing lesions mapped to a hippocampal circuit	91
The challenges of anti-tau therapeutics in Alzheimer disease	90
Neuroinflammation predicts cognitive decline in FTD	88
Implications of AD plasma and PET biomarker discordance	87
Gene therapy effective in model of infantile parkinsonism	86
MRI-based deep learning for TLE diagnosis	84
Diversity, equity and inclusion in neurology	84
APOE ε4 influences Parkinson disease progression	81
Brain imaging illuminates cognitive impairment in multiple sclerosis	81
Author Correction: Viral pathogens increase risk of neurodegenerative disease	75
First trials test targeting of α-synuclein for Parkinson disease	74
Gene therapy for seizures in focal cortical dysplasia	74
Parkinson disease pathology can originate in the kidney	73
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	68
Management of freezing of gait — mechanism-based practical recommendations	68
Precision neuroimmunology in multiple sclerosis — the horizon is near	68
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	67
α-Synuclein pathology as a target in neurodegenerative diseases	66
Evidence for altered astrocyte function in Duchenne muscular dystrophy	66
New IDEAS about amyloid, race and dementia disparities	65
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	64
Food is brain medicine — relevance and translation to neurology	63
Neurosteroids alleviate seizures in rats	62
Glymphatic dysfunction in PD clinical progression	61
A new biological classification for Parkinson disease	60
Thalamic inflammation — a therapeutic target for brain injury?	60
Exosomal microRNA is promising biomarker in PD	58
Addressing disparities in neurology by building the workforce in LMICs	57
Ultrasound ablation treatment for PD	55
Spinal cord stimulation for the treatment of chronic pain	55
Coeliac disease as a model for understanding multiple sclerosis	54
The global and regional burden of diabetic peripheral neuropathy	52
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	51
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	51
Apparent changes in the epidemiology and severity of multiple sclerosis	51
The role of glial cells in multiple sclerosis disease progression	50
From the prodromal stage of multiple sclerosis to disease prevention	49

Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	49
Is Alzheimer disease a disease?	48
Synaptic degeneration in Alzheimer disease	48
Hypothalamus loses control in migraine	46
Hypothyroidism is associated with dementia risk	42
X-chromosome variants and PD in Latin America	42
Oligomeric tau could spread through synapses in AD	42
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	41
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	41
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	41
Neurofilament light chain induces neuroinflammation	40
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	40
The inter-relationship between delirium and dementia: the importance of delirium prevention	38
Global epidemiology of migraine and its implications for public health and health policy	38
Cognitive impairment and World Trade Centre-related exposures	38
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	37
CAR T cells offer hope in glioblastoma	37
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	36
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	36
Moving towards meaningful patient and public engagement	35
Risk locus for paediatric astrocytoma identified	35
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	35
Dual function of biomolecular condensates	35
α-Synuclein seeds in amyotrophic lateral sclerosis	35
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	33
Change in stroke outcomes over 20 years	33
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	32
New developments in guidelines for brain death/death by neurological criteria	32
Prognostic plasma biomarkers for spinal cord injury	31
Origins and immunopathogenesis of autoimmune central nervous system disorders	31
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	31
Huntington disease-like 2: insight into neurodegeneration from an African disease	31
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	31
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	30
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	29
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	28
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	27
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	27
Positron emission tomography in multiple sclerosis — straight to the target	27
Twin study probes non-heritable immune aspects of multiple sclerosis	24
Deep learning distinguishes tauopathies	24
Neurogenesis altered in multiple neurodegenerative diseases	22
Multiple sclerosis treatment blunts SARS-CoV-2 antibody response	22
Charting brain development across the human lifespan	21
High rate of epilepsy in young individuals who died with COVID-19	21
Serum NfL as an MS biomarker	20
Does antiherpetic antiviral therapy reduce the risk of dementia?	20
Genome-wide analysis furthers decoding of Alzheimer disease genetics	20
John Q. Trojanowski	19
ALS pathogenesis linked to actin barrier collapse	19
AI and protein structure and function in neurological disease: relevance to disease management	19
The murky waters of sex differences in post-stroke cognitive impairment	19
Aberrant protein networks in Alzheimer disease	19
Author Correction: The complex aetiology of cerebral palsy	17
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	17
BCAS1+ oligodendrocytes aid remyelination in MS	17
AI aces diagnosis of chronic ataxias	17
Pharmacological rehabilitation for stroke	16
Addressing disparities in the global epidemiology of stroke	16
Pathogenetic mechanisms and treatment targets in cerebral malaria	16
Alzheimer disease in African American individuals: increased incidence or not enough data?	16
Neuroprognostication: a conceptual framework	15
Clocking the age of Parkinson disease onset	14
Molecular biomarkers for vascular cognitive impairment and dementia	14
Nanoprobe for blood–brain barrier changes	13
Nusinersen treatment response markers	13
Effects of diet on MS onset and course	13
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	13
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	12
Predictive tools in psychosis: what is ‘good enough’?	12
Altered muscle cholesterol transport in ALS	12
Sex and gender in neurodevelopmental conditions	11
Alzheimer disease seen through the lens of sex and gender	11
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	11
Mechanistic insights into the interaction between epilepsy and sleep	11
Markers help to predict dementia with Lewy bodies	10
Multidimensional MRI detects astrogliosis	10
Seizure-associated changes in the Golgi apparatus	10
Advances in the therapeutic algorithm for myasthenia gravis	9
Shared glial pathology in HD and schizophrenia	9

Evidence-based clinical care and policy making for schizophrenia	9
Parkinson disease pathology in inflammatory bowel disease	9
Multisite chronic pain: a risk factor for dementia	9
Advancing neurogenetics in Africa: past achievements, current developments and shaping the future	8
Inclusion in neurological research: empowering people living with neurological diseases	8
Author Correction: Why functional neurological disorder is not feigning or malingering	8
Psychiatric sequelae of traumatic brain injury — future directions in research	8
The missing X factor in Alzheimer disease	8
Walking the Talk for Dementia — an experience to break down barriers	8
Sensory feedback in upper limb prosthetics: advances and challenges	7
Recycling brain scans with AI	7
T cell–microbiome communication influences disease in MS model	7
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis	7
Novel oxytocin spray is beneficial in ASD	7
TP73 variants implicate apoptosis in amyotrophic lateral sclerosis pathogenesis	7
Immune mechanisms and shared immune targets in neurodegenerative diseases	7
A global view of the genetic basis of Alzheimer disease	7
Vulnerable dopamine neurons identified	7
Artificial intelligence in epilepsy — applications and pathways to the clinic	7
Ageing reduces potential for remyelination in multiple sclerosis	6
Review and update of the concept of embolic stroke of undetermined source	6
Identification of neurons involved in schizophrenia	6
PD pathology spread linked to mtDNA damage	6
Peripheral B cells altered in Parkinson disease	6
MS drug beneficial in an underrepresented group	6
Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA	6
Glymphatic dysfunction detected in bvFTD	6
27-Hydroxycholesterol propagates α-synuclein pathology in Parkinson disease	6
Calcium dysregulation could underlie lysosomal impairment in AD	5
Oestrogen receptor variants linked to AD traits	5
Multifaceted roles of APOE in Alzheimer disease	5
Addressing disparities in neurology by enhancing inclusive practice	5
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis	5
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	5
Engineered TREM2 antibody clears Aβ in mice	5
From precision diagnosis to precision treatment in epilepsy	5
White matter transcriptome altered in CTE	5
Early-stage Alzheimer disease: getting trial-ready	5
Astrocytes in the initiation and progression of epilepsy	5
BTK inhibitor falters in multiple sclerosis trials	5
Functional brain networks in the evaluation of patients with neurodegenerative disorders	5
Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums	5
Brain–machine interface treats pain in rats	5
Dementia risk scores in diverse populations	5
Breakthrough technology restores function after complete paralysis	5
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	5
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	5
Stem cells show promise in Parkinson disease	5
Implications of immunometabolism for smouldering MS pathology and therapy	5
EBV-specific T cells in multiple sclerosis	5
Microglial senescence is a potential therapeutic target for Alzheimer disease	5
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	4
Oligodendrocyte progenitor cell transplant for MS	4
New CRISPR-based strategies for Alzheimer disease	4
Closing the loop for patients with Parkinson disease: where are we?	4
Skin α-synuclein differentiates synucleinopathies	4
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?	4
Neurology under the midnight sun: EAN Congress 2024 comes to Helsinki	4
Monitoring disease onset in amyotrophic lateral sclerosis	4
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms	4
Exosomal microRNAs may aid differential diagnosis of movement disorders	4
Insights into the toxic effects of mutant huntingtin	4
Novel plasma markers for Parkinson disease	4
Publisher Correction: Microglial transcriptomics meets genetics: new disease leads	4
Sleep and circadian disturbances in children with neurodevelopmental disorders	4
Addressing disparities in neurology by identifying gaps in hospital care	4
Reply to: Questioning the cycad theory of Kii ALS–PDC causation	4
GluA2 modulator targets excitotoxicity in MS	3
Finger-prick blood test for Alzheimer disease	3
WNT receptor variant linked to synaptic degeneration	3
New local therapy strategies for brain tumours	3
Glioblastoma tackled with oncolytic virus	3
Women’s neurology: a growing subspeciality to tackle sex and gender disparities	3
‘On-demand’ gene therapy for epilepsy	3
A biomarker for mild cognitive impairment	3
Bruton tyrosine kinase inhibitors for multiple sclerosis	3
Early-onset dementia in autism spectrum disorder	3
Parkinson disease and air pollution: does what we breathe matter?	3
Autoimmune encephalitis-associated epilepsy	3
Treating epilepsy in forcibly displaced persons: timely, necessary, affordable	3
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	3
Identifying molecular targets in trigeminal nociception	3
Levosimendan fails to improve respiratory function in amyotrophic lateral sclerosis	3
Epstein–Barr virus and MS — a causal link	3
The importance of getting evidence into practice	3
Exome sequencing identifies risk variants for AD	3
Disentangling clinical and biological trajectories of neurodegenerative diseases	3
Lost empathy in FTD linked to prefrontal hypoexcitability	2
Publisher Correction: Functional brain networks in the evaluation of patients with neurodegenerative disorders	2
Mind over microplastics — what we still don’t know	2
Obesity-associated immune exhaustion accelerates AD pathology	2
Phagocytes linked to cognitive dysfunction in neuro-HIV	2
Treatments for AD: towards the right target at the right time	2
Navigating complexities of racial disparities in Alzheimer disease biomarkers	2
Serum sphingosine 1-phosphate as a marker of PD progression	2